Why the study?
Viral myocarditis is a serious clinical condition characterized by cardiac inflammation, and while dapagliflozin exhibits protective effects in inflammatory diseases, its effect on viral myocarditis has not been studied.
Does dapagliflozin alleviate myocardial inflammation and improve outcomes in a mouse model of Coxsackievirus B3-induced acute viral myocarditis?
Does dapagliflozin alleviate myocardial inflammation and improve outcomes in a mouse model of Coxsackievirus B3-induced acute viral myocarditis?
Dapagliflozin demonstrates protective effects in a preclinical model of acute viral myocarditis by reducing inflammation and improving survival and cardiac function.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dapagliflozin in viral myocarditis; should not change practice pending human trials.
Viral myocarditis (VMC), which is most prevalently caused by Coxsackievirus B3 (CVB3) infection, is a serious clinical condition characterized by cardiac inflammation. Dapagliflozin, a kind of sodium glucose co-transporters 2(SGLT-2) inhibitor, exhibited protective effects on plenty of inflammatory diseases, while its effect on viral myocarditis has not been studied. Recently we found the protective effect of dapagliflozin on VMC. After CVB3 infection, dapagliflozin were given orally to Balb/c male mice for 8 days and then the severity of myocarditis was assessed. Our results indicated that dapagliflozin significantly alleviated the severity of viral myocarditis, elevated the survival rate, and ameliorated cardiac function. Besides, dapagliflozin can decrease the level of proinflammatory cytokines included IL-1β, IL-6, TNF-α. Furthermore, dapagliflozin can inhibit macrophages differentiate to classically activated macrophages (M1) in cardiac tissue and activate the Stat3 signal pathway which is reported to promote polarization of the alternatively activated macrophage (M2). In conclusion, our study demonstrates that dapagliflozin alleviates myocardial inflammation by regulating the macrophage polarization and Stat3-related pathways in coxsackie virus B3-induced acute viral myocarditis.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: